SNORA37: A Non-Coding RNA Molecule Regulating MicroRNA Expression

Target Name: SNORA37

NCBI ID: G677819

SNORA37

Other Name(s): small nucleolar RNA, H/ACA box 37 | ACA37 | Small nucleolar RNA, H/ACA box 37

SNORA37: A Non-Coding RNA Molecule Regulating MicroRNA Expression

SNORA37, also known as small nucleolar RNA (snRNA), is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in various organisms, including humans. It is a part of the H/ACA box family of snRNAs , which are known for their ability to interact with the protein H/ACA and influence gene expression.

The H/ACA box is a conserved region found in the non-coding RNAs that is responsible for binding to the protein H/ACA. This protein plays a critical role in the regulation of gene expression by binding to specific DNA sequences and affecting the activity of various enzymes. The H/ACA box is a well-established drug target and has been the focus of intense research in recent years due to its potential as a therapeutic agent.

While the exact mechanism of how H/ACA box interacts with the RNA molecule is not yet fully understood, it is known that the H/ACA box can modulate the activity of various RNA-protein complexes, including the RNA-protein interactions that are critical for the regulation of gene expression.

One of the key functions of SNORA37 is its role in the regulation of gene expression. It is well established that SNORA37 plays a critical role in the regulation of microRNA (miRNA) expression, which are small non-coding RNAs that play a central role in the regulation of gene expression.

MicroRNAs are designed to target specific mRNAs for degradation by the 26S rRNA-protein complex, which is a key component of the translation machinery. By targeted degradation of target mRNAs, microRNAs can effectively reduce the levels of these mRNAs and determine the expression of various genes.

SNORA37 is one of the key components of the H/ACA box family of snRNAs and has been shown to play a critical role in the regulation of microRNA expression. It is well established that SNORA37 interacts with the H/ACA protein and can modulate the activity of the H/ACA-interactive microRNAs.

In addition to its role in the regulation of microRNA expression, SNORA37 is also involved in the regulation of other RNA molecules, including ribulose-1,6-bisfuranose (RuBisCO) RNA-protein interactions and the translation of RNA molecules.

SNORA37 has also been shown to play a critical role in the regulation of gene expression in various diseases, including cancer. For example, it has been shown to play a critical role in the regulation of the expression of genes involved in cell growth, apoptosis ( programmed cell death), and angiogenesis (the formation of new blood vessels).

In conclusion, SNORA37 is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in various organisms, including humans. Its role in the regulation of microRNA expression and other RNA molecules makes it an attractive target for further research and development as a therapeutic agent. While further studies are needed to fully understand the exact mechanism of how SNORA37 interacts with the H/ACA protein and other RNA molecules, its potential as a drug target is already being explored in various studies.

Protein Name: Small Nucleolar RNA, H/ACA Box 37

The "SNORA37 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA37 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets